Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: Clinical results and effects on microenvironment and neo-angiogenic biomarkers

Haematologica

Volumn 97, Issue 3, 2012, Pages 416-422

  Zaja, Francesco ^a   De Luca, Stefano ^a   Vitolo, Umberto ^b   Orsucci, Lorella ^b   Levis, Alessandro ^c   Salvi, Flavia ^c   Rusconi, Chiara ^d   Ravelli, Erika ^d   Tucci, Alessandra ^e   Bottelli, Chiara ^e   Balzarotti, Monica ^f   Brusamolino, Ercole ^g   Bonfichi, Maurizio ^g   Pileri, Stefano A ^h   Sabattini, Elena ^h   Volpetti, Stefano ^a   Monagheddu, Chiara ^b   Vacca, Angelo ⁱ   Ria, Roberto ⁱ   Fanin, Renato ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c SC Ematologia AO SS Antonio e Biagio e C Arrigo   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e SPEDALI CIVILI   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h Dipartimento di Ematologia e Scienze Oncologiche 'L e A Seragnoli'   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

Author keywords

Dexamethasone; Lenalidomide; Mantle cell lymphoma; Relapsed refractory disease; Salvage treatment

Indexed keywords

ACETYLSALICYLIC ACID; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; FIBROBLAST GROWTH FACTOR; LENALIDOMIDE; LEVOFLOXACIN; METHOTREXATE; PLATELET DERIVED GROWTH FACTOR; RITUXIMAB; SCATTER FACTOR; VASCULOTROPIN; VINCRISTINE; WARFARIN;

ADULT; AGED; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CANCER RELAPSE; CARDIOTOXICITY; CHOLECYSTITIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEMUR FRACTURE; HUMAN; HYPOTENSION; INTESTINE PERFORATION; LEUKOPENIA; LUNG DISEASE; MACROPHAGE; MALE; MANTLE CELL LYMPHOMA; MICROVASCULATURE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYCOSIS; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REFRACTORY PERIOD; SALVAGE THERAPY; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; DEXAMETHASONE; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECURRENCE; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84857740069     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.051813     Document Type: Article

References (17)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780-95.
2. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008;142(2):149-65.
3. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511-8.
4. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 2009;69(18):7347-56.
5. Zhang L, Kosek J, Schafer P, Bartlett JB. Correlation of tumoricidal activity of lenalidomide against hematologic tumor cells with cyclin D1/D2 expression and effect on tumor-suppressor gene upregulation [abstract]. J Clin Oncol. 2010;28: Abstract 8090.
6. Gaidarova S, Corral LG, Glezer E, Schafer PH, Lopez-Girona A. Treatment of MCL cells with combined rituximab and lenalidomide enhances NK-mediated synapse formation and cell killing [abstract]. ASH Annual Meeting Abstracts 2009;114:Abstract 1687.
7. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(30):4952-7.
8. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2009;27(32):5404-9.
9. Witzig TE, Vose JM, Luigi Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of singleagent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622-7.
10. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344-9.
11. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011;35(3):380-6.
12. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133-42.
13. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-32.
14. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-86.
15. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14(14):4650-7.
16. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108(2):618-21.
17. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103(5):1787-90.